Drugs / TYF-ABCD1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT03727555 | Aug 2025 → Dec 2027 expected | adrenoleukodystrophy | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TYF-ABCD1 | “using a high-safety, high-efficiency, self-inactivating lentiviral vector (LV) TYF-ABCD1 to functionally correct the defective gene” NCT03727555 ↗ |
| Action | Restore | “to functionally correct the defective gene” NCT03727555 ↗ |
| Route | Intrathecal | “via intrathecal (IT) and intravenous (IV) injections” NCT03727555 ↗ |
| Route | Intravenous | “via intrathecal (IT) and intravenous (IV) injections” NCT03727555 ↗ |